奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙一线治疗无症状/轻度症状及有症状转移性去势抵抗性前列腺癌的疗效与安全性:3期PROpel试验分析
PROpel试验的事后探索性亚组分析显示,在无症状/轻度症状的转移性去势抵抗性前列腺癌患者中,奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙的中位影像学无进展生存期为27.6个月对19.1个月(HR 0.59,95%CI 0.46-0.76);在有症状患者中为14.1个月对13.8个月(HR 0.78,95%CI 0.54-1.13)。
要点
- 无症状/轻度症状患者中位rPFS:奥拉帕利联合阿比特龙27.6个月 vs 安慰剂联合阿比特龙19.1个月(HR 0.59)。
- 有症状患者中位rPFS:奥拉帕利联合阿比特龙14.1个月 vs 安慰剂联合阿比特龙13.8个月(HR 0.78,95%CI 0.54-1.13)。
- 无症状/轻度症状患者中位OS:奥拉帕利联合阿比特龙未达到 vs 安慰剂联合阿比特龙39.5个月(HR 0.77)。
核心结论
- 奥拉帕利联合阿比特龙在无症状/轻度症状和有症状的一线转移性去势抵抗性前列腺癌患者中均提供疗效获益,无症状/轻度症状患者获益更大。
研究设计与样本
- PROpel(NCT03732820)为3期试验,患者按1:1随机接受奥拉帕利(300 mg每日两次)或安慰剂联合阿比特龙(1000 mg每日一次)加泼尼松/泼尼松龙(5 mg每日两次)。
- 本次为事后探索性亚组分析,无症状/轻度症状定义为简明疼痛评估量表简表(BPI-SF)第3项评分<4分且未使用阿片类药物,有症状定义为BPI-SF第3项评分≥4分和/或使用阿片类药物。
- 无症状/轻度症状组560例,有症状组183例。
主要发现
- 无症状/轻度症状患者中位rPFS:奥拉帕利联合阿比特龙27.6个月 vs 安慰剂联合阿比特龙19.1个月(HR 0.59,95%CI 0.46-0.76)。
- 有症状患者中位rPFS:奥拉帕利联合阿比特龙14.1个月 vs 安慰剂联合阿比特龙13.8个月(HR 0.78,95%CI 0.54-1.13)。
- 无症状/轻度症状患者中位OS:奥拉帕利联合阿比特龙未达到 vs 安慰剂联合阿比特龙39.5个月(HR 0.77,95%CI 0.59-1.00)。
- 有症状患者中位OS:奥拉帕利联合阿比特龙22.9个月 vs 安慰剂联合阿比特龙22.8个月(HR 0.82,95%CI 0.58-1.16)。
- 其他结局在亚组间无有意义的差异。
临床怎么用
- 作者认为,奥拉帕利联合阿比特龙在无症状/轻度症状和有症状的一线转移性去势抵抗性前列腺癌患者中均提供疗效获益,无症状/轻度症状患者获益更大。
局限性
- 本次分析为事后探索性亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In PROpel (NCT03732820), olaparib + abiraterone resulted in a statistically significant radiographic progression-free survival (rPFS) benefit and numerically prolonged overall survival (OS) versus placebo + abiraterone in first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) patients. Here, we report post hoc exploratory subgroup analyses in patients with asymptomatic/mildly symptomatic or symptomatic disease at baseline. METHODS: Patients were randomised 1:1 to olaparib (300 mg b.i.d.) or placebo with abiraterone (1000 mg o.d.) + prednisone/prednisolone (5 mg b.i.d.). For this post hoc exploratory analysis, patients with a Brief Pain Inventory-Short Form (BPI-SF) item 3 score of <4 and no opiate use were classified as asymptomatic/mildly symptomatic; those with a BPI-SF item 3 score of ≥4 and/or opiate use were classified as symptomatic. Subgroup analyses included investigator-assessed rPFS, OS, objective response rate, time to second progression or death, health-related quality of life, and safety. KEY FINDINGS AND LIMITATIONS: The median rPFS in asymptomatic/mildly symptomatic patients (n = 560) was 27.6 mo for olaparib + abiraterone versus 19.1 mo for placebo + abiraterone (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.46-0.76). For symptomatic patients (n = 183), equivalent values were 14.1 versus 13.8 mo (HR, 0.78; 95% CI, 0.54-1.13). At the final planned OS analysis, the median OS in asymptomatic/mildly symptomatic patients was not reached for olaparib + abiraterone versus 39.5 mo for placebo + abiraterone (HR, 0.77; 95% CI, 0.59-1.00). For symptomatic patients, equivalent values were 22.9 versus 22.8 mo (HR, 0.82; 95% CI, 0.58-1.16). Other outcomes showed no meaningful differences between the subgroups. CONCLUSIONS AND CLINICAL IMPLICATIONS: Olaparib + abiraterone provided efficacy benefits in 1L mCRPC patients with either asymptomatic/mildly symptomatic or symptomatic disease. A larger benefit occurred in asymptomatic/mildly symptomatic patients. PATIENT SUMMARY: PROpel, a phase 3 clinical trial, looked at whether combining olaparib with abiraterone delays the progression of patients' cancer compared with placebo plus abiraterone. Patients with or without pain symptoms associated with metastatic castration-resistant prostate cancer were eligible for enrolment into the trial. Results showed that olaparib plus abiraterone reduced the risk of disease progression and death, with a larger benefit observed in patients without or with mild pain symptoms than in those with pain symptoms.
引用
- Clarke NW, Armstrong AJ, Oya M, et al. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. 2024. PMID: 39384451. doi:10.1016/j.euo.2024.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。